OLD Mission Capital LLC Makes New $48.94 Million Investment in Sanofi $SNY

Key Points

• OLD Mission Capital LLC invested approximately $48.94 million in Sanofi by purchasing 882,400 shares, making it the firm's 14th largest holding.
• Sanofi reported $0.90 earnings per share for the last quarter, which missed analysts' consensus estimates by $0.06, although revenue exceeded expectations at $11.34 billion.
• Several analysts have upgraded their ratings on Sanofi, with the stock receiving an average rating of "Buy" and a consensus price target of $62.00.

OLD Mission Capital LLC purchased a new position in shares of Sanofi (NASDAQ:SNY - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 882,400 shares of the company's stock, valued at approximately $48,938,000. Sanofi accounts for approximately 0.6% of OLD Mission Capital LLC's investment portfolio, making the stock its 14th largest holding.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNY. Brighton Jones LLC lifted its stake in Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock worth $261,000 after purchasing an additional 1,869 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Sanofi by 3.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 164,538 shares of the company's stock worth $7,936,000 after buying an additional 5,198 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Sanofi by 33.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,174 shares of the company's stock worth $153,000 after buying an additional 792 shares in the last quarter. Hsbc Holdings PLC increased its holdings in shares of Sanofi by 258.6% during the fourth quarter. Hsbc Holdings PLC now owns 35,033 shares of the company's stock worth $1,695,000 after buying an additional 25,263 shares in the last quarter. Finally, Integrated Wealth Concepts LLC increased its holdings in shares of Sanofi by 14.4% during the fourth quarter. Integrated Wealth Concepts LLC now owns 16,344 shares of the company's stock worth $788,000 after buying an additional 2,052 shares in the last quarter. Institutional investors own 14.04% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on SNY shares. JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a report on Friday, August 8th. Morgan Stanley set a $56.00 price target on shares of Sanofi in a report on Monday, June 2nd. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Wall Street Zen upgraded Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Finally, Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Sanofi in a research report on Tuesday, August 5th. Three equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Sanofi currently has a consensus rating of "Buy" and an average price target of $62.00.

Sanofi Stock Down 0.9%

NASDAQ:SNY traded down $0.46 on Monday, hitting $49.48. 2,437,389 shares of the company's stock were exchanged, compared to its average volume of 2,317,348. The firm has a 50-day moving average price of $48.81 and a 200-day moving average price of $51.57. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. Sanofi has a 52 week low of $44.73 and a 52 week high of $60.12. The company has a market cap of $121.50 billion, a P/E ratio of 12.04, a price-to-earnings-growth ratio of 1.18 and a beta of 0.51.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). The business had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The company's quarterly revenue was down 7.0% compared to the same quarter last year. During the same period last year, the firm earned $1.73 earnings per share. As a group, analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.